⤵️
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

pharmather.com/news/pharmathe…

#cepharanthine

$PHRRF $PHRM $PHRM.C
$PHRX $LMLLF

⤵️
PharmaTher Provides Update for Expected FDA Approval of #Ketamine

Assigned FDA approval goal date of April 29, 2024, is still on track

Press Release: pharmather.com/news/pharmathe…

$PHRRF $PHRM

⤵️
December 2023 Corporate Presentation

Click here for PDF version:
pharmather.com/uploads/1/2/5/…

Visit pharmather.com

$PHRRF $PHRM $PHRM.C

---
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ ( #Ketamine )

FDA assigns GDUFA goal date of April 29, 2024

Press Release: pharmather.com/news/pharmathe…

$PHRRF $PHRM $PHRM.C

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ ( #Ketamine ) to the FDA

Press release: pharmather.com/news/pharmathe…

$PHRRF $PHRM $PHRM.C

September 2023 Corporate Presentation

Click here:
pharmather.com/uploads/1/2/5/…

#Ketamine #psychedelics #cepharanthine

$PHRRF $PHRM $PHRM.C

PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

Press release:
pharmather.com/news/pharmathe…

$PHRRF $PHRM

PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ #ketamine to the FDA

Press Release: globenewswire.com/news-release/2…

$PHRRF $PHRM $PHRM.C

PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ ( #ketamine ) in the U.S.

Press release:
pharmather.com/news/pharmathe…

$PHRRF $PHRM

PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ ( #ketamine ) in the U.S.

Press release: pharmather.com/news/pharmathe…

$PHRRF $PHRM $PHRM.C

PharmaTher Holdings Provides Corporate Update

Press release: pharmather.com/news/pharmathe…

$PHRRF $PHRM $PHRM.C

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ ( #ketamine ) for the Treatment of #Parkinson 's Disease

Press release: pharmather.com/news/pharmathe…

$PHRRF $PHRM $PHRM.C

Update of Type C Meeting with the FDA for KETARX™ #ketamine in #Parkinson 's Disease

Press release: globenewswire.com/en/news-releas…

$PHRRF $PHRM $PHRM.C

Today is #RareDiseaseDay

Our progress with #ketamine includes 5 orphan drug destinations granted by the FDA

1. #RettSyndrome
2. Ischemia-reperfusion injury
3. Status Epilepticus
4. #ALS
5. Complex Regional Pain Syndrome

#RareDiseaseDay 2023

Hiring VP, Commercial Development.

Lead commercialization of racemic #ketamine products in various concentrations, dosages (RTU) delivery (IV, IM, SQ).

Experience selling specialty injectables (ANDA, 505b2) to hospitals, pharmacies, clinics, etc.

Email CV: [email protected]

Another reason why PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE:PHRM) is focused on #ketamine

A very good study evaluating #ketamine as a potential treatment for Borderline Personality Disorder. 👏 Sarah

Paper: nature.com/articles/s4138…

Thank you Thomas George for having me speak. As always 🔥 on your spaces. FYI to my followers I joined in at 44:20…the good stuff 😉

Discuss FDA 505(b)(2) Pathway for NDA of KETARX™ #Ketamine On-Body Pump System

Press release:
pharmather.com/news/pharmathe…

$PHRRF $PHRM $PHRM.C